Data on the pharmacogenetic markers of the effectiveness of treatment of children with atopic asthma are presented, which reveal a variability of the response to treatment with glucocorticosteroids, leukotriene receptor antagonists, and b2-adrenoreceptor agonists in children with bronchial asthma. The association of genotype Gly/Glyl6 gene b2-adrenergic receptor with insufficient effect of the therapy with short-acting b2-agonists is demonstrated. The Glyl6 allele, CYP2D6 - 1934GGd contributes to the formation of a phenotype with severe asthma and tolerance to therapy with b2-agonists and inhaled corticosteroids.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
markers effectiveness
8
effectiveness treatment
8
treatment children
8
children atopic
8
[pharmacogenetic markers
4
atopic bronchial
4
bronchial asthma]
4
asthma] data
4
data pharmacogenetic
4
pharmacogenetic markers
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!